Distinguishing plasmablastic lymphoma (PBL) from ALK-positive large B-cell lymphoma (ALK+ LBCL) is vital due to their overlapping morphologic and immunophenotypic features, yet different clinical behaviors and therapeutic implications. This evidence concerns the gene ALK and B-cell non-Hodgkin lymphoma.